Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker
The purpose of this study is to see if the Artifical Pancreas Platform (AP Platform = Cell Phone + Closed Loop Control) can successfully control blood sugar in people with type 1 diabetes mellitus on insulin pump therapy in a hospital setting. Investigators will also be studying to see if information about heart rate can help the AP Platform reduce hypoglycemia related to exercise.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker|
- Hypoglycemic events [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]Plasma glucose based number of hypoglycemic events, defined as consecutive plasma readings below 70mg/dl to measure the capacity of the system to protect patients against the risk of hypoglycemia. Two events separated by only one YSI value over 70 are considered to form a single event.
- Low Blood Glucose Index [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]A measure of the risk of hypoglycemia. It quantifies both duration and amplitude of the risk for hypoglycemia.
- Exercise maximum glucose drop [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]Defined as the difference between plasma glucose at onset of exercise and the minimum glucose reached up to one hour after exercise.
- Plasma glucose rebound [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]Defined as the difference between plasma glucose at onset of exercise and the maximum glucose reached up to two hours after exercise (if treatment by the nursing staff occurs the last two measures are invalid).
- Blood glucose ranges [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]Percent time spent within safe (70-250) and target (70-180) ranges.
|Study Start Date:||May 2012|
|Estimated Study Completion Date:||February 2013|
|Estimated Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Experimental: Experimental Condition: (Heart-Rate Informed SSM+HMM)
An experimental condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is informed about heart rate
Device: Heart rate informed SSM+HMM
The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
No Intervention: Control Condition (SSM+HMM)
A control condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is not informed about heart rate.
The combination of the Control to Range system and the cell phone is called the "Artificial Pancreas (AP) Platform". The purpose of this study is to see if this investigational technology can help control blood sugar in people with type 1 diabetes mellitus on insulin pump therapy can be successfully used and supervised in a hospital setting. This study is also being done to see if giving information about heart rate to the Closed-to-Range System can reduce hypoglycemia as it relates to exercise. Subjects will exercise on an exercise bike in the clinical research unit. During one exercise testing session, the Control to Range System will receive information about your heart rate (Experimental Condition). During the other exercise testing session, the Control to Range System will not receive information about your heart rate (Control Condition). This part of the study is being done to see whether heart rate information helps the Control to Range System reduce the occurrences of exercise-related hypoglycemia.
The Control to Range system has two parts (modules) that can work together or separately.
A. The Safety Supervision Module helps to prevent low blood sugars. It can reduce the amount of basal insulin that the pump is delivering and alert you if carbohydrates are needed to help prevent a low blood sugar. This module will be active at all times during the operation of the Control to Range System.
B. The Hyperglycemia Mitigation Module helps to prevent high blood sugars. It can instruct the insulin pump to deliver small boluses to help prevent high blood sugar. It can also help warn you of a possible pump problem if the blood sugar level is not responding to the insulin as it should.
The Control to Range System works with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL) during the day and help avoid hypoglycemia during the night.
|Contact: Laura Kollar, RN||434-982-6479||LLK7M@VIRGINIA.EDU|
|Contact: Mary Oliveri, CCRP||434-982-0602||MC7M@VIRGINIA.EDU|
|United States, Virginia|
|University of Virginia||Recruiting|
|Charlottesville, Virginia, United States, 22908|
|Principal Investigator: Marc Breton, Ph.D.|
|Sub-Investigator: Boris Kovatchev, Ph.D.|
|Sub-Investigator: Stacey M. Anderson, M.D.|
|Sub-Investigator: Sue Brown, M.D.|
|Sub-Investigator: Stephen Patek, Ph.D.|
|Principal Investigator:||Marc Breton, Ph.D.||University of Virginia Center for Diabetes Technology|